A $93 million Series A round is backing Estuary’s one-time kidney gene therapy program as the company seeks to compete across emerging modalities for autosomal dominant polycystic kidney disease (ADPKD). The funding is aimed at building clinical momentum for a potential durable treatment model, aligning with investor interest in curative or functional-cure approaches in rare and high-burden renal disease. The report frames the investment as part of a broader arms race among drug developers testing gene and gene-adjacent therapies in ADPKD, a disease where current management focuses on slowing progression rather than stopping cyst growth at the source. While the article’s detail is limited, it positions the round as validation of the program’s development thesis and readiness to advance toward later preclinical and clinical milestones. For biotech professionals, the immediate signal is capital flow toward one-time treatment concepts in nephrology—an area where market size and unmet need are attracting new funding even as modality risk remains high.